Table 1.
Patient Demographics and Baseline Characteristics (APaT Population)
| Characteristic | MK-8353 50 mg + Selumetinib 25 mg n = 3 |
MK-8353 100 mg + Selumetinib 50 mg n = 12 |
MK-8353 150 mg + Selumetinib 75 mg n = 15 |
Total N = 30 |
|---|---|---|---|---|
| Age, median (range), y |
59.0 (48−64) |
59.5 (26−73) |
66.0 (27−78) |
61.5 (26−78) |
| Sex | ||||
| Men | 3 (100) | 5 (42) | 8 (53) | 16 (53) |
| Women | 0 | 7 (58) | 7 (47) | 14 (47) |
| ECOG performance status score | ||||
| 0 | 1 (33) | 3 (25) | 5 (33) | 9 (30) |
| 1 | 2 (67) | 9 (75) | 10 (67) | 21 (70) |
| Received previous cancer therapy | 3 (100) | 12 (100) | 13 (87) | 28 (93) |
| First line | 1 (33) | 2 (17) | 1 (7) | 4 (13) |
| Second line | 1 (33) | 3 (25) | 5 (33) | 9 (30) |
| Third line | 1 (33) | 6 (50) | 2 (13) | 9 (30) |
| Fourth line | 0 | 0 | 3 (20) | 3 (10) |
| ≥ Fifth line | 0 | 1 (8) | 2 (13) | 3 (10) |
| Missing | 0 | 0 | 2 (13) | 2 (7) |
APaT, all patients as treated; ECOG, Eastern Cooperative Oncology Group
Data are presented as n (%) unless specified otherwise